- Home
- ORKA vs KROS Comparison
ORKA vs KROS Comparison
Compare ORKA & KROS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ORKA
- KROS
- Stock Information
- Founded
- ORKA 2004
- KROS 2015
- Country
- ORKA United States
- KROS United States
- Employees
- ORKA N/A
- KROS N/A
- Industry
- ORKA Biotechnology: In Vitro & In Vivo Diagnostic Substances
- KROS Biotechnology: Pharmaceutical Preparations
- Sector
- ORKA Health Care
- KROS Health Care
- Exchange
- ORKA Nasdaq
- KROS Nasdaq
- Market Cap
- ORKA 580.3M
- KROS 565.0M
- IPO Year
- ORKA N/A
- KROS 2020
- Fundamental
- Price
- ORKA $20.43
- KROS $15.71
- Analyst Decision
- ORKA Strong Buy
- KROS Buy
- Analyst Count
- ORKA 7
- KROS 14
- Target Price
- ORKA $43.00
- KROS $20.56
- AVG Volume (30 Days)
- ORKA 520.4K
- KROS 370.6K
- Earning Date
- ORKA 11-12-2025
- KROS 11-05-2025
- Dividend Yield
- ORKA N/A
- KROS N/A
- EPS Growth
- ORKA N/A
- KROS N/A
- EPS
- ORKA N/A
- KROS 0.47
- Revenue
- ORKA N/A
- KROS $232,844,000.00
- Revenue This Year
- ORKA N/A
- KROS $5,998.31
- Revenue Next Year
- ORKA N/A
- KROS N/A
- P/E Ratio
- ORKA N/A
- KROS $33.68
- Revenue Growth
- ORKA N/A
- KROS 85820.30
- 52 Week Low
- ORKA $5.49
- KROS $9.12
- 52 Week High
- ORKA $31.13
- KROS $72.37
- Technical
- Relative Strength Index (RSI)
- ORKA 68.72
- KROS 53.11
- Support Level
- ORKA $18.19
- KROS $15.00
- Resistance Level
- ORKA $21.18
- KROS $16.57
- Average True Range (ATR)
- ORKA 1.42
- KROS 0.53
- MACD
- ORKA 0.41
- KROS -0.06
- Stochastic Oscillator
- ORKA 89.03
- KROS 47.77
About ORKA Oruka Therapeutics Inc. Common Stock
Oruka Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing novel monoclonal antibody therapeutics for psoriasis (PsO) and other inflammatory and immunology (I&I) indications. Its lead program, ORKA-001, is designed to target the p19 subunit of interleukin-23 (IL-23p19) for the treatment of PsO. The company's co-lead program, ORKA-002, is designed to target interleukin-17A and interleukin-17F (IL-17A/F) for the treatment of PsO, psoriatic arthritis (PsA), and other conditions. These programs each bind their respective targets at high affinity and incorporate half-life extension technology to increase exposure and decreasing dosing frequency.
About KROS Keros Therapeutics Inc.
Keros Therapeutics Inc is a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel treatments for patients suffering from hematological, pulmonary, and cardiovascular disorders with high unmet medical needs. The company's protein therapeutic product candidate, KER-050, is being developed for the treatment of low blood cells counts, or cytopenias, including anemia and thrombocytopenia, in patients with myelodysplastic syndromes, or MDS, and in patients with myelofibrosis.